在持久的左心室辅助装置患者中Vericiguat的经验
Boaz Elad1, Changhee Lee1, Julia Baranowska1
1Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons and NewYork-Presbyterian Hospital, New York, New York, USA.
Artificial organs
|April 1, 2025
概括
维里西瓜特对于使用左心室辅助器件 (LVAD) 的患者来说似乎是安全的,显示出改善心脏功能和降低肺压力的趋势. 需要进一步的研究来证实在这个人群中的疗效.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 医疗器械 医疗器械
背景情况:
- 持久的左心室辅助装置 (LVAD) 对于高级心力衰竭 (HF) 管理至关重要.
- 针对血管功能的药物Vericiguat可能为LVAD患者提供额外的好处.
研究的目的:
- 评估Vericiguat在已经支持LVADs的患者中的安全性和有效性.
- 评估Vericiguat对血红相容性相关不良事件 (HRAE) 和Vericiguat特定不良事件的影响.
- 为了确定纽约心脏协会 (NYHA) 功能类和N-终端亲B型尿素 (NT-proBNP) 水平的变化.
主要方法:
- 八名接受Vericiguat治疗的HeartMate3 LVAD患者的回顾性分析.
- 安全结果包括HRAE和Vericiguat不良事件.
- 效率结果集中在NYHA类和NT-proBNP水平的变化上.
主要成果:
- 在研究队列中没有报告HRAE,Vericiguat不良事件或死亡.
- 观察到右心室中风工作指数的统计学上显著增加 (p=0.043).
- 观察到肺毛细管压力下降和心脏指数增加的趋势,尽管在统计学上并不显著.
结论:
- 在LVAD患者中,维瑞西瓜特治疗显示出良好的安全性.
- 初步发现表明有提高疗效的潜力,需要进一步调查.
相关概念视频
01:26Heart Failure Drugs: Inotropic Agents
445
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
445
01:22Heart Failure Drugs: Diuretics
298
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
298
01:22Heart Failure Drugs: β-Blockers
284
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
284